Zobrazeno 1 - 10
of 256
pro vyhledávání: '"Berna Oksuzoglu"'
Autor:
Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür, Funda Yılmaz, Oğuzhan Selvi, Dilek Erdem, Esin Avşar, Nail Paksoy, Necla Demir, Sema Sezgin Göksu, Sema Türker, Ertuğrul Bayram, Abdüssamet Çelebi, Hatice Yılmaz, Ömer Faruk Kuzu, Seda Kahraman, İvo Gökmen, Abdullah Sakin, Ali Alkan, Erdinç Nayır, Muzaffer Uğraklı, Ömer Acar, İsmail Ertürk, Hacer Demir, Ferit Aslan, Özlem Sönmez, Taner Korkmaz, Özde Melisa Celayir, İbrahim Karadağ, Erkan Kayıkçıoğlu, Teoman Şakalar, İlker Nihat Öktem, Tülay Eren, Enes Erul, Eda Eylemer Mocan, Ziya Kalkan, Nilgün Yıldırım, Yakup Ergün, Baran Akagündüz, Serdar Karakaya, Engin Kut, Fatih Teker, Burçin Çakan Demirel, Kubilay Karaboyun, Elvina Almuradova, Olçun Ümit Ünal, Abdilkerim Oyman, Deniz Işık, Kerem Okutur, Buğra Öztosun, Burcu Belen Gülbağcı, Mehmet Emin Kalender, Elif Şahin, Mustafa Seyyar, Özlem Özdemir, Fatih Selçukbiricik, Metin Kanıtez, İsa Dede, Mahmut Gümüş, Erhan Gökmen, Arzu Yaren, Serkan Menekşe, Senar Ebinç, Sercan Aksoy, Gökşen İnanç İmamoğlu, Mustafa Altınbaş, Bülent Çetin, Başak Oyan Uluç, Özlem Er, Nuri Karadurmuş, Atike Pınar Erdoğan, Mehmet Artaç, Özgür Tanrıverdi, İrfan Çiçin, Mehmet Ali Nahit Şendur, Esin Oktay, İbrahim Vedat Bayoğlu, Semra Paydaş, Adnan Aydıner, Derya Kıvrak Salim, Çağlayan Geredeli, Tuğba Yavuzşen, Mutlu Doğan, İlhan Hacıbekiroğlu
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment
Externí odkaz:
https://doaj.org/article/042edc2981bf4d52a01526b7a7c03f4f
Autor:
Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür, Funda Yılmaz, Oğuzhan Selvi, Dilek Erdem, Esin Avşar, Nail Paksoy, Necla Demir, Sema Sezgin Göksu, Sema Türker, Ertuğrul Bayram, Abdüssamet Çelebi, Hatice Yılmaz, Ömer Faruk Kuzu, Seda Kahraman, İvo Gökmen, Abdullah Sakin, Ali Alkan, Erdinç Nayır, Muzafer Uğraklı, Ömer Acar, İsmail Ertürk, Hacer Demir, Ferit Aslan, Özlem Sönmez, Taner Korkmaz, Özde Melisa Celayir, İbrahim Karadağ, Erkan Kayıkçıoğlu, Teoman Şakalar, İlker Nihat Öktem, Tülay Eren, Enes Erul, Eda Eylemer Mocan, Ziya Kalkan, Nilgün Yıldırım, Yakup Ergün, Baran Akagündüz, Serdar Karakaya, Engin Kut, Fatih Teker, Burçin Çakan Demirel, Kubilay Karaboyun, Elvina Almuradova, Olçun Ümit Ünal, Abdilkerim Oyman, Deniz Işık, Kerem Okutur, Buğra Öztosun, Burcu Belen Gülbağcı, Mehmet Emin Kalender, Elif Şahin, Mustafa Seyyar, Özlem Özdemir, Fatih Selçukbiricik, Metin Kanıtez, İsa Dede, Mahmut Gümüş, Erhan Gökmen, Arzu Yaren, Serkan Menekşe, Senar Ebinç, Sercan Aksoy, Gökşen İnanç İmamoğlu, Mustafa Altınbaş, Bülent Çetin, Başak Oyan Uluç, Özlem Er, Nuri Karadurmuş, Atike Pınar Erdoğan, Mehmet Artaç, Özgür Tanrıverdi, İrfan Çiçin, Mehmet Ali Nahit Şendur, Esin Oktay, İbrahim Vedat Bayoğlu, Semra Paydaş, Adnan Aydıner, Derya Kıvrak Salim, Çağlayan Geredeli, Tuğba Yavuzşen, Mutlu Doğan, İlhan Hacıbekiroğlu
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/62814a4471cb45089f6723c0cccc8157
Autor:
Suayib Yalcin, Faysal Dane, Berna Oksuzoglu, Nuriye Yildirim Ozdemir, Abdurrahman Isikdogan, Metin Ozkan, Guzin Gonullu Demirag, Hasan Senol Coskun, Bulent Karabulut, Turkkan Evrensel, Mehmet Ali Ustaoglu, Feyyaz Ozdemir, Hande Turna, Tugba Yavuzsen, Faruk Aykan, Alper Sevinc, Hakan Akbulut, Deniz Yuce, Mutlu Hayran, Saadettin Kilickap
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background Combination of gemcitabine and nab-paclitaxel has superior clinical efficacy than gemcitabine alone. Nevertheless, health-related quality of life. (QoL) associated with this combination therapy when administered at first-line in a
Externí odkaz:
https://doaj.org/article/1ae3c043ebb54a6c82250c0cb4ea7be9
Publikováno v:
Journal of Oncological Sciences, Vol 4, Iss 3, Pp 119-124 (2018)
Purpose: The aim of this study is to analyze the demographic, histopathologic features of Neuroendocrine tumor (NET) cases and to underline the treatment approaches over seven years period in a high-volume cancer center. Methods: This study designed
Externí odkaz:
https://doaj.org/article/4ceed126db044a3d9d51753a81be36d8
Autor:
Ayse Gok Durnali, Fatma Paksoy Turkoz, Fisun Ardic Yukruk, Saadet Tokluoglu, Omer Kamil Yazici, Ayse Demirci, Oznur Bal, Selay Gundogdu Buyukbas, Onur Esbah, Berna Oksuzoglu, Necati Alkis
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0152621 (2016)
Osteosarcomas with lung metastases are rather heterogenous group. We aimed to evaluate the clinicopathological characteristics and outcomes of osteosarcoma patients with lung metastases and to compare the synchronous and metachronous lung metastatic
Externí odkaz:
https://doaj.org/article/4e2e68daa8ca4237b11d37b65b9ed04e
Autor:
Arife Ulas, Fatma Paksoy Turkoz, Kamile Silay, Saadet Tokluoglu, Nilufer Avci, Berna Oksuzoglu, Necati Alkis
Publikováno v:
PLoS ONE, Vol 9, Iss 12, p e114471 (2014)
We aimed to establish a laboratory prognostic index (LPI) in advanced non-small cell lung cancer (NSCLC) patients based on hematologic and biochemical parameters and to analyze the predictive value of LPI on NSCLC survival.The study retrospectively r
Externí odkaz:
https://doaj.org/article/6032908549874f0f9cf78544de607693
Autor:
Ahmet Bilici, Omer Fatih Olmez, Muhammed Ali Kaplan, Berna Oksuzoglu, Ahmet Sezer, Nuri Karadurmus, Erdem Cubukcu, Mehmet Ali Nahit Sendur, Sercan Aksoy, Dilek Erdem, Gul Basaran, Burcu Cakar, Abdallah T. M. Shbair, Cagatay Arslan, Ahmet Taner Sumbul, Sema Sezgin Goksu, Ibrahim Karadag, Irfan Cicin, Mahmut Gumus, Fatih Selcukbiricik, Hakan Harputluoglu, Umut Demirci
Publikováno v:
Acta Oncologica. 62:381-390
Autor:
Muhammet Bekir Hacioglu, Bulent Erdogan, Murat Bardakcı, Efnan Algın, Burcu Gulbagcı, Ilhan Hacibekiroglu, Jamshid Hamdard, Omer Fatih Olmez, Hadi Akkus, Berna Oksuzoglu, Sema Sezgin Goksu, Shute Ailia Dae, Ahmet Taner Sumbul, Muzaffer Ugraklı, Mustafa Karaagac, Elif Sahin, Devrim Cabuk, Ozden Ozer, Tugba Yavuzsen, Rukiye Arıkan, Osman Köstek, Muhammed Mustafa Atcı, Abdullah Sakin, Adem Deligonul, Duygu Bayır, Murat Dincer, Oktay Unsal, Ozan Yazıcı, Esra Zeynelgil, Ahmet Gulmez, Hakan Harputluoglu, Cihan Erol, Mehmet Ali Nahit Sendur, Aydin Aytekin, Baran Akagunduz, Irem Oner, Ozlem Er, Bugra Oztosun, Mahmut Gumus, Fatih Selcuk Biricik, Musa Baris Aykan, Nuri Karadurmus, Ezgi Degerli, Nebi Serkan Demirci, Esma Turkmen, Teoman Şakalar, Saban Secmeler, Ozgur Tanrıverdi, Ali Alkan, Yasemin Kemal, Ibrahim Cil, Caglar Unal, Yakup Iriagaç, Ozkan Alan, Sevinc Balli, Yuksel Urun, Erkan Ozcan, Nazım Serdar Turhal, Irfan Cicin
Publikováno v:
Head & Neck.
Background: Most of the studies on salivary gland cancers are limited for various reasons such as being single-center, small number of patients, including only major or minor SGCs, or only including epidemiological data. Methods: A total of 37 medica
Autor:
Mutlu Dogan, Cengiz Karacin, Omur Kaman, Zarife Melda Bulut, Gamze Kiziltan, Berna Oksuzoglu, Lutfi Dogan
Purpose:Role of neoadjuvant chemotherapy(NAC) & modified preoperative endocrine prognostic index (mPEPI) score after NAC is unclear in locally advanced HER2(-) breast cancer(LA-HnLBC).We evaluated prognostic & predictive factors for NAC in LA-HnLBC r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4dfc0e47e6d13e3e792ad9a7e9d1d11f
https://doi.org/10.21203/rs.3.rs-2756296/v1
https://doi.org/10.21203/rs.3.rs-2756296/v1
Autor:
Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz-Josef Klümpen, Stephen L Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W Valle, Li Yu, Usha Malhotra, Abby B Siegel, Julien Edeline, Arndt Vogel, Mehmet Akce, Immaculada Ales Diaz, Gustavo Alves, Sumitra Anand, Cagatay Arslan, Jamil Asselah, Eric Assenat, Francine Aubin, Li-Yuan Bai, Yuxian Bai, Susan Bates, Stephen Begbie, Irit Ben-Aharon, Nina Beri, Marie-Luise Berres, Jean-Frederic Blanc, Ivan Borbath, Robert Bordonaro, Giovanni Brandi, Adam Burgoyne, Kritiya Butthongkomvong, Ke Cao, Marcela Carballido, Marcos Camandaroba, Stephan Lam Chang, Jen-Shi Chen, Ming-Huang Chen, Xiaoming Chen, Ashley Cheng, Tai-Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joelle Collignon, Antonio Cubillo Gracian, Sarah Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith De Vos, Maria Diab, Jacob Easaw, Martin Eatock, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernandez, Richard Finn, Fabio Franke, Masayuki Furukawa, Olumide Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gumus, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoglu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Juneul Hwang, Mevlude Inanc, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jimenez Fonseca, Warren Joubert, Jitlada Juengsamarn, Diego Kaen, Masahi Kanai, Stefan Kasper-Virchow, Ghazaleh Kazemi, Fergal Kelleher, Robin Kelley, Jin Won Kim, Jong Gwang Kim, Ana Beatriz Kinupe Abrahao, Heinz Klumpen, Mark Kochenderfer, Fatih Kose, Ho Ching Lam, Choong-kun Lee, Hyun Woo Lee, Margaret Lee, Myung Ah Lee, Wai Man Sarah Lee, Samuel Le Sourd, Dongliang Li, Wei Li, Houjie Liang, Tingbo Liang, Chun Sen Lim, Brian Lingerfelt, Charles Lopez, John Low, Teresa Macarulla Mercade, David Malka, Yimin Mao, Gianluca Masi, Steven McCune, Ray McDermott, Elaine McWhirter, Guillermo Mendez, Michele Milella, Tomonori Mizutani, Camila Moniz, Luisa Morales, Andres Jesús Munoz Martin, Bruno Nervi, Nuttapong Ngamphaiboon, Sang Cheul Oh, Berna Oksuzoglu, Darryl Outlaw, Mustafa Ozguroglu, Ozgur Ozyilkan, Claudio Painemeal, Yueyin Pan, Chuang Peng, Caroline Petorin, Denis Pezet, Derek Power, Shukui Qin, Aflah Roohullah, Hyewon Ryu, Pamela Salman, Rita Sasidharan, Taroh Satho, Kornelius Schulze, Martin Scott-Brown, Ruben Segovia, Thomas Seufferlin, Salvatore Siena, Isabelle Sinapi, Cristina Smolenschi, Tianqiang Song, Aumkhae Sookprasert, Nopadol Soparattanapaisarn, Naureen Starling, Stacey Stein, Salomon Stemmer, Haichuan Su, Rie Sugimoto, Thatthan Suksombooncharoen, Vincent Tam, Ai Lian Tan, Chih Kiang Tan, Suebpong Tanasanvimon, Giuseppe Tonini, Giampaolo Tortora, Akihito Tsuji, Rodrigo Uribe, Marino Venerito, Helena Verdaguer Mata, Ana Paula Victorino, James Wade, Dirk Thomas Waldschmidt, Lu Wang, Wan Zamaniah Wan Isahk, Harpeet Wasan, Rui Weschenfelder, Chun Yin Wong, Yoke Fui Wong, Suayib Yalcin, Patricio Yanez Weber, Xuezhong Yang, Hisateru Yasui, Ozan Yazici, Chia-Jui Yen, Jieer Ying, Wenchang Yu, Haitao Zhao
Publikováno v:
The KEYNOTE-966 Investigators, Kelley, R K, Ueno, M, Yoo, C, Finn, R S, Furuse, J, Ren, Z, Yau, T, Klümpen, H-J, Chan, S L, Ozaka, M, Verslype, C, Bouattour, M, Park, J O, Barajas, O, Pelzer, U, Valle, J W, Yu, L, Malhotra, U, Siegel, A B, Edeline, J & Vogel, A 2023, ' Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet . https://doi.org/10.1016/S0140-6736(23)00727-4
The Lancet
The Lancet, 2023, 401 (10391), pp.1853-1865. ⟨10.1016/S0140-6736(23)00727-4⟩
KEYNOTE-966 Investigators 2023, ' Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet, vol. 401, no. 10391, pp. 1853-1865 . https://doi.org/10.1016/S0140-6736(23)00727-4
The Lancet, 401(10391), 1853-1865. Elsevier Limited
The Lancet
The Lancet, 2023, 401 (10391), pp.1853-1865. ⟨10.1016/S0140-6736(23)00727-4⟩
KEYNOTE-966 Investigators 2023, ' Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet, vol. 401, no. 10391, pp. 1853-1865 . https://doi.org/10.1016/S0140-6736(23)00727-4
The Lancet, 401(10391), 1853-1865. Elsevier Limited
Background: Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67e2bc96e0f72cde5bf243ad704e6b14
https://pure.manchester.ac.uk/ws/files/261634672/Pembrolizumab_in_combination_with_gemcitabine_and_cisplatin_compared_with_gemcitabine_and_cisplatin_alone_for_advanced_biliary...28Mar2023.docx
https://pure.manchester.ac.uk/ws/files/261634672/Pembrolizumab_in_combination_with_gemcitabine_and_cisplatin_compared_with_gemcitabine_and_cisplatin_alone_for_advanced_biliary...28Mar2023.docx